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ess: ljoos@uhbs.ch (L.Summary Bronchoalveolar lavage (BAL) is a useful tool in the diagnosis of
pulmonary infections in immunocompromised patients. We aimed to compare the
spectrum of infectious pulmonary complications diagnosed using BAL in a large
consecutive cohort of immunocompromised patients.
The diagnostic yield of 1066 BAL specimens was analyzed in 4 different groups of
immunocompromised patients (HIV; solid organ transplants; high-dose chemotherapy
and/or stem cell transplants; other immunosuppressive therapy) suffering from
fever, respiratory symptoms and/or infiltrates on chest X-ray. Specimens were
analyzed for bacteria, mycobacteria, fungi, Pneumocystis jiroveci, cytomegalovirus
(CMV) and other viruses. Two time periods were compared (1992–1996;
1997–2003).
The overall diagnostic yield of BAL was 34% for bacteria, 22% for CMV, 15% for
P. jiroveci, 6% for other viruses, 6% for mycobacteria and 2% for aspergillus. There
were significant changes in the pattern of opportunistic infections between the 2
time periods. Mycobacterial infections decreased considerably in the HIV group (17.9
vs. 8.5%, P ¼ 0:02), while the incidence of P. jiroveci decreased mainly in the
transplant group (32.6 vs. 7.9%, Po0:00001).
This study demonstrates a changed pattern of pulmonary infections in
immunocompromised patients diagnosed by BAL. The overall diagnostic yield of
BAL remains high in immunocompromised patients with respiratory symptoms.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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L. Joos et al.94Introduction elsewhere.10 For BAL, 3 50ml of pyrogen-freeThe development of pulmonary symptoms and
infiltrates is a frequent life-threatening complica-
tion in immunocompromised patients, which re-
quires early diagnosis for optimal treatment.1
Bronchoalveolar lavage (BAL) is a successful meth-
od to diagnose infections in these patients.2–6
Within the last few years, new therapeutic
agents were introduced in treatment regimens of
immunocompromised patients. Highly active anti-
retroviral therapy (HAART), introduced in 1996/97,
led to an overall decrease in opportunistic infec-
tions and to prolonged survival in human immuno-
deficiency virus (HIV) patients.7,8 New potent
immunosuppressive compounds, such as tacroli-
mus, mycofenolate mofetil (MMF) and rapamycin
have also been introduced around the same time to
prevent graft rejection in solid organ transplant
recipients. Immunosuppressive therapy predisposes
patients to an increased risk of bacterial infections
and also to opportunistic infection such as Pneu-
mocystis jiroveci pneumonia (PCP), invasive asper-
gillosis, and cytomegalovirus (CMV) pneumonitis.
BAL is sensitive in detecting PCP4 and tracheobron-
chial aspergillosis.5,9
The aim of the present study was to assess the
diagnostic yield of BAL in the diagnosis of pulmon-
ary infections in various groups of immunocompro-
mised patients. Additionally, the impact of HAART
and new immunosuppressive drugs in regard to the
pattern of pulmonary infections was studied by
comparing the years 1992–1996 and 1997–2003.Methods
Over a 12-year period (1992–2003), a total of 1066
consecutive diagnostic bronchoscopies with BAL
were performed in four groups of immunocompro-
mised patients: HIV-positive patients (n ¼ 420),
stem cell transplant recipients and patients under-
going high-dose chemotherapy for haematological
diseases (including ALL, AML, CLL, Myeloma, and
Lymphoma, n ¼ 374), solid-organ transplant reci-
pients (including renal transplants, heart, lung, and
liver transplants, n ¼ 173) and other immunocom-
promised patients which included patients with
autoimmune disease (Wegener’s granulomatosis,
systemic lupus erythematosus, rheumatoid arthri-
tis, and polymyalgia rheumatica) or interstitial lung
diseases receiving immunosuppressive therapy
(n ¼ 99). Indications for BAL were fever, respira-
tory symptoms, and/or infiltrates on chest X-ray.
Diagnostic bronchoscopy was performed under
local anaesthesia and sedation as describedsterile 0.9% NaCl solution were instilled into the
middle lobe or lingula in patients with diffuse
disease and in patients with heterogeneous disease
the segment with the most prominent radiological
infiltrate. BAL fluid was recovered by suction or
gravity. BAL fluid was sent for bacterial, mycobac-
terial, fungal and viral culture. Mouth flora and
candida grown from BAL were not regarded as
relevant pathogens and therefore not included in
the analysis. CMV culture was performed by shell
vial assay, spinning BAL onto human embryonic
fibroblasts and determining the presence of CMV
immediate early antigen by immunofluorescence
and CMV DNA by in situ hybridisation after 1 and 5
days, respectively.6 Conventional cytology was also
performed. Following centrifugation, the cell pel-
let was resuspended in cell culture medium, and
smears were prepared. Routine staining included
Grocott for PCP, monoclonal antibodies for CMV and
Papanicolau.
Results were divided into two time periods:
1992–1996 and 1997–2003, the latter era in which
HAART and new immunosuppressive agents were
introduced at our institution. Statistical analysis
was performed using chi-square test and Fisher’s
exact test with a level of significance at Po0:05.Results
The total number of BAL procedures performed in
patients with high-dose chemotherapy/stem cell
transplantation, solid organ transplantation and
the other immunosuppressed group increased while
the number in HIV patients markedly decreased
since the introduction of HAART (290/534 (54%) vs.
130/532 (24%) BAL, Po0:0001). This fall in the
number of BAL procedures in the HIV population has
been despite an increase of the total number of
patients treated for HIV at our centre (1992–1996:
236742 patients per year [mean7SD], 1997–2003:
477779.9 patients per year).11
The overall diagnostic yields of BAL for bacteria,
mycobacteria, aspergillus, CMV, other viruses and
PCP and in the four subgroups are summarised in
Table 1. The percentage of bacterial infections was
higher in the HIV patients (202/420, 48%) and the
other immunocompromised group (37/99, 37%)
compared to the solid organ transplant (45/173,
26%) and stem cell transplant plus high chemother-
apy group (74/374, 20%). The bacteria recovered
included mainly Staphylococcus, Streptococcus
pneumoniae, Haemophilus influenzae, Moraxella,
Pseudomonas and Escherichia coli. Many of the
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Table 1 Diagnostic yield of BAL in immunocompromised patients.
Diagnostic yield HIV Stem cell
transplants
chemotherapy
Solid organ
transplants
Other
immunosuppressed
Total
Bacteria (n, %) 202 (48%) 74 (20%) 45 (26%) 37 (37%) 358 (34%)
Mycobacteria (n, %) 63 (15%) 0 0 (0%) 1 (1%) 64 (6%)
Aspergillus (n, %) 1 (0.2%) 10 (3%) 6 (4%) 3 (3%) 20 (2%)
CMV (n, %) 119 (28%) 45 (12%) 46 (27%) 23 (23%) 233 (22%)
Other viruses (n, %) 37 (9%) 16 (4%) 23 (13%) 7 (7%) 83 (8%)
PCP (n, %) 110 (26%) 13 (4%) 25 (15%) 8 (8%) 156 (15%)
Total n of BAL 420 374 173 99 1066
Keys: CMV, Cytomegalovirus; PCP, Pneumocystis jiroveci.
Other viruses included respiratory syncycial virus, herpes simplex virus, adenovirus.
Table 2 Patterns of infections in all patients.
1992–1996
(n ¼ 534)
1997–2003
(n ¼ 532)
P-value
Bacteria 208 (39%) 150 (28%) ns
Mycobacteria 53 (18%) 11 (9%) o0.0001
Aspergillus 2 (0.4%) 18 (3.4%) o0.001
CMV 123 (23%) 110 (21%) ns
Other viruses 33 (6%) 50 (9%) o0.05
PCP 110 (21%) 46 (9%) o0.00001
Keys: CMV, Cytomegalovirus; PCP, Pneumocystis jiroveci.
Table 3 Patterns of infections in patients with
HIV.
1992–1996
(n ¼ 290)
1997–2003
(n ¼ 130)
P-value
Bacteria 157 (54%) 45 (35%) 0.03
Mycobacteria 52 (18%) 11 (9%) 0.02
Aspergillus 0 1 —
CMV 80 (28%) 39 (30%) ns
Other viruses 25 (9%) 12 (9%) ns
PCP 84 (29%) 26 (20%) ns
Keys: CMV, Cytomegalovirus; PCP, Pneumocystis jiroveci.
Table 4 Patterns of infections in stem cell
transplant and high-dose chemotherapy group.
1992–1996
(n ¼ 169)
1997–2003
(n ¼ 205)
P-value
Bacteria 29 (17%) 45 (22%) ns
Mycobacteria 0 0 —
Aspergillus 2 (1%) 8 (4%) 0.04
CMV 26 (15%) 19 (9%) ns
Other viruses 3 (2%) 13 (6%) 0.03
PCP 6 (4%) 7 (3%) ns
Keys: CMV, Cytomegalovirus; PCP, Pneumocystis jiroveci.
BAL in immunocompromised patients 95samples contained more than one infectious agent.
Mycobacteria were only found in HIV patients and in
one case of lung fibrosis treated with steroids. The
incidence of CMV infections was particularly lower
in patients with haematological disorders com-
pared to other patient groups (Po0:0001). (Table 2)
Analysis of the two time periods revealed a
significant decrease in bacterial and mycobac-
terial infections diagnosed at BAL in HIV patients
(Table 3). Although, the overall number of BAL
procedures performed since 1997 were markedly
reduced in the HIV population, there was no
significant change in the chances of diagnosing
PCP infections at BAL. However, the occurrence of
PCP infections was significantly reduced in the solid
organ transplant and other immunocompromised
patient populations (Tables 4–6). The incidence of
overall CMV infections diagnosed at BAL remained
constant over the studied 12-year period. Human
herpesvirus 8 (HHV-8) was detected in a total of 20
cases, the majority (18/20) in the period from
1992–1996 with pulmonary Kaposi’s sarcoma.
Demographic data of study patients is sum-
marised in Table 7.Discussion
BAL is a safe and often diagnostic procedure that
typically results in a change in therapy.12,13 There
has been a change in the overall health status and
infectious complications over the past several years
owing the advent of HAART and potent immuno-
suppressive agents.12 The findings of our study
demonstrate that the yield of BAL in the diagnosis
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host remains high over the last decade although
there is a shift in the pattern of infectious micro-
organisms detected by BAL. To the authors’ current
knowledge this is the largest consecutive cohort of
immunocompromised patients undergoing BAL.
In patients with HIV infection, bacterial infec-
tions were significantly reduced in the HAART era;
however, they continue to be seen most commonly
in the HIV population. Mycobacterial infections
were also significantly reduced in the HAART era. It
is interesting to note that in our large cohort,
mycobacterial infections in the post-HAART era
were observed only in the HIV population. This
suggests that routine testing for mycobacteria at
BAL should be undertaken in HIV patients. As the
risk of having mycobacterial infection is lower in
the other immunosuppressed host not living inTable 6 Patterns of infections in the other
immunocompromised group.
1992–1996
(n ¼ 29)
1997–2003
(n ¼ 70)
P-value
Bacteria 10 (35%) 27 (39%) ns
Mycobacteria 1 (3%) 0 —
Aspergillus 0 3 (4%) —
CMV 8 (28%) 15 (21%) ns
Other viruses 0 7 (10%) —
PCP 5 (17%) 3 (5%) 0.04
Keys: CMV, Cytomegalovirus; PCP, Pneumocystis jiroveci.
Table 5 Patterns of infections in solid organ
transplant recipients.
1992–1996
(n ¼ 46)
1997–2003
(n ¼ 127)
P-value
Bacteria 12 (26%) 33 (26%) ns
Mycobacteria 0 0 —
Aspergillus 0 6 (4.7%) —
CMV 9 (20%) 37 (29%) ns
Other viruses 5 (11%) 18 (14%) ns
PCP 15 (33%) 10 (8%) o0.0001
Keys: CMV, Cytomegalovirus; PCP, Pneumocystis jiroveci.
Table 7 Demographic data of all patient groups.
Demographic data HIV Stem cell transpl
chemotherapy
Age (years), mean 39.7 46.4
Age (years), range 23–75 12–80
Gender (% male) 73.3 44.1endemic areas, testing for mycobacteria in BAL
may be restricted to only selected cases with a high
index of clinical suspicion. A decrease in the overall
incidence of PCP infections has been observed in
HIV patients in previous studies.14 Despite there
was no significant reduction in the percentage of
PCP in HIV patients referred for BAL, there was a
marked overall decrease in the incidence of PCP in
the HAARTera. We support this by the fact that the
number of individuals treated for HIV in the
outpatient clinic of our hospital has markedly
increased since 1997, whilst the number of BAL
procedures performed in the HIV population has
dramatically reduced since 1997 (Table 3). This
reduction in the number of bronchoscopies per-
formed in the HIV population is consistent with the
results of Taggart et al.15 Detection of HHV-8 in BAL
which is highly associated with pulmonary Kaposi’s
sarcoma became rare in recent years.3 This is in
agreement with other studies demonstrating a
drastic reduction in hospital admission rates and
mortality due to AIDS-defining diseases.16 There
was a trend in the reduction of CMV in stem cell
transplant and high-dose chemotherapy patients
but no change in the other immunosuppressed
patient groups. The reduction in CMV infection
diagnosed by BAL in patients with stem cell
transplant and high-dose chemotherapy might be
due to the more common use of CMV antigenemia
to diagnose CMV infection leading to a preemptive
treatment of the infection and also due to the use
of prophylactic anti-viral regimens.17
Aspergillus was isolated in the BAL specimens of
only 20 patients (2%). Aspergillus infections were
particularly low in the HIV population. Since 1997,
aspergillus was more commonly isolated in the
patients with stem cell transplant, high-dose
chemotherapy, solid organ transplant and other
immunocompromised patients. The low incidence
of aspergillus infection in the haematology-related
immunosuppression patients is probably low as BAL
is not sensitive in detecting invasive pulmonary
aspergillosis in neutropenic patients as it is more
vascular invasive and does not involve the airways
commonly in contrast to lung transplant recipi-
ents.4,5 There was a significant reduction in theants Solid organ
transplants
Other
immunosuppressed
55.2 57.1
19–76 25–76
56.9 40.7
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plant recipients and the other immunocompro-
mised patients. This can be attributed to
prophylaxis with trimethoprim/sulphomethoxa-
zole. The detection of viruses other than CMV
(Herpes simplex virus, respiratory syncytial virus,
adenovirus) was significantly increased in the later
time period. With an incidence of 7% overall, these
pathogens should not be underestimated.
The retrospective design of this study did not
allow us to accurately comment on parameters
such as treatment, detailed bacterial analysis,
disease severity, and mortality. Moreover, the
dichotomisation in two eras is arbitrary, however
it based on radical changes in treatment of HIV and
use of immunosuppressive agents in the transplant
population. A randomised study with BAL may be
difficult to design, however, the current study
clearly shows the continued utility of BAL in the
immunocompromised host using a large sample
size. A prospective observational study to assess
the impact of BAL on patient outcomes might
further support this approach.
To summarise, there is a change in the pattern of
pulmonary infections diagnosed by BAL since the
introduction of HAART and new immunosuppressive
agents. The findings of our study demonstrate that
the number of BAL procedure referrals in HIV
patients has dramatically reduced since the HAART
era. Amongst HIV patients referred for a BAL,
bacteria, CMV and PCP are the commonly encoun-
tered organisms. In stem cell transplant or high-
dose chemotherapy patients, bacterial infections
are most commonly encountered and there is
increased isolation of aspergillus in BAL specimens.
In solid organ transplant recipients and other
immunocompromised group, CMV and bacterial
infections are common and there is a reduction in
the isolation of PCP since 1997. To conclude, BAL
continues to be an important diagnostic tool with a
high yield in immunocompromised patients.References
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